Sandbox:YK

ACC/AHA Guideline Template

Class I

"1. RECOMMENDATION 1 HERE(Level of Evidence: A)"

"2. RECOMMENDATION 2 HERE(Level of Evidence: B)"

Class III (Harm)

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class III (No Benefit)

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIa

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIb

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary(DO NOT EDIT)

Renin-Angiotensin-Aldosterone System Inhibitors (DO NOT EDIT)

Class I

"1. An angiotensin-converting enzyme inhibitor should be administered within the first 24 hours to all patients with STEMI with anterior location, HF, or ejection fraction less than or equal to 0.40, unless contraindicated(Level of Evidence: A)"

"2. An angiotensin receptor blocker should be given to patients with STEMI who have indications for but are intolerant of angiotensin-converting enzyme inhibitors(Level of Evidence: B)"

"3. An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an angiotensin-converting enzyme inhibitor and beta blocker and who have an ejection fraction less than or equal to 0.40 and either symptomatic HF or diabetes mellitus(Level of Evidence: B)"

Class IIa

"1. Angiotensin-converting enzyme inhibitors are reasonable for all patients with STEMI and no contraindications to their use (Level of Evidence: A)"

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary(DO NOT EDIT)

Coronary Artery Bypass Graft Surgery: Recommendations(DO NOT EDIT)

CABG in Patients With STEMI

Class I

"1. Urgent CABG is indicated in patients with STEMI and coronary anatomy not amenable to PCI who have ongoing or recurrent ischemia, cardiogenic shock, severe HF, or other high-risk features(Level of Evidence: B)"

"2. CABG is recommended in patients with STEMI at time of operative repair of mechanical defects (Level of Evidence: B)"

Class IIa

"1. The use of mechanical circulatory support is reasonable in patients with STEMI who are hemodynamically unstable and require urgent CABG (Level of Evidence: C)"

Class IIb

"1. Emergency CABG within 6 hours of symptom onset may be considered in patients with STEMI who do not have cardiogenic shock and are not candidates for PCI or fibrinolytic therapy (Level of Evidence: C)"

Timing of Urgent CABG in Patients With STEMI in Relation to Use of Antiplatelet Agents

Class I

"1. Aspirin should not be withheld before urgent CABG (Level of Evidence: C)"

"2. Clopidogrel or ticagrelor should be discontinued at least 24 hours before urgent on-pump CABG, if possible(Level of Evidence: B)"

"3. Short-acting intravenous GP IIb/IIIa receptor antagonists (eptifibatide, tirofiban) should be discontinued at least 2 to 4 hours before urgent CABG (Level of Evidence: B)"

"4. Abciximab should be discontinued at least 12 hours before urgent CABG (Level of Evidence: B)"

Class IIb

"1. Urgent off-pump CABG within 24 hours of clopidogrel or ticagrelor administration might be considered, especially if the benefits of prompt revascularization outweigh the risks of bleeding (Level of Evidence: B)"

"2. Urgent CABG within 5 days of clopidogrel or ticagrelor administration or within 7 days of prasugrel administration might be considered, especially if the benefits of prompt revascularization outweigh the risks of bleeding (Level of Evidence: C)"

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary

Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals

Class I

"1. All communities should create and maintain a regional system of STEMI care that includes assessment and continuous quality improvement of emergency medical services and hospital-based activities. Performance can be facilitated by participating in programs such as Mission: Lifeline and the Door-to-Balloon Alliance(Level of Evidence: B)"

"2. Performance of a 12-lead electrocardiogram (ECG) by emergency medical services personnel at the site of first medical contact (FMC) is recommended in patients with symptoms consistent with STEMI(Level of Evidence: B)"

"3. Reperfusion therapy should be administered to all eligible patients with STEMI with symptom onset within the prior 12 hours(Level of Evidence: A)"

"4. Primary PCI is the recommended method of reperfusion when it can be performed in a timely fashion by experienced operators(Level of Evidence: A)"

"5. Emergency medical services transport directly to a PCI-capable hospital for primary PCI is the recommended triage strategy for patients with STEMI, with an ideal FMC-to-device time system goal of 90 minutes or less(Level of Evidence: B)"

"6. Immediate transfer to a PCI-capable hospital for primary PCI is the recommended triage strategy for patients with STEMI who initially arrive at or are transported to a non–PCI-capable hospital, with an FMC-to-device time system goal of 120 minutes or less(Level of Evidence: B)"

"7. In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI at non–PCI-capable hospitals when the anticipated FMC-to-device time at a PCI-capable hospital exceeds 120 minutes because of unavoidable delays (Level of Evidence: B)"

"8. When fibrinolytic therapy is indicated or chosen as the primary reperfusion strategy, it should be administered within 30 minutes of hospital arrival(Level of Evidence: B)"

Class IIa

"1. Reperfusion therapy is reasonable for patients with STEMI and symptom onset within the prior 12 to 24 hours who have clinical and/or ECG evidence of ongoing ischemia. Primary PCI is the preferred strategy in this population (Level of Evidence: B)"

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (DO NOT EDIT)

Heart Failure

Class I

"1.Control of resting heart rate using either a beta blocker or nondihydropyridine calcium channel antagonist is recommended for patients with persistent or permanent AF and compensated HF with preserved ejection fraction (Level of Evidence: B)"

"2. In the absence of pre-excitation, intravenous beta-blocker administration (or a nondihydropyridine calcium channel antagonist in patients with HFpEF) is recommended to slow the ventricular response to AF in the acute setting, with caution needed in patients with overt congestion, hypotension, or HF with reduced left ventricular ejection fraction(Level of Evidence: B)"

"3. In the absence of pre-excitation, intravenous digoxin or amiodarone is recommended to control heart rate acutely in patients with HF(Level of Evidence: B)"

"4.Assessment of heart rate control during exercise and adjustment of pharmacological treatment to keep the rate in the physiological range is useful in symptomatic patients during activity.(Level of Evidence: C)"

"5. Digoxin is effective to control resting heart rate in patients with HF with reduced ejection fraction(Level of Evidence: B)"

Class III (Harm)

"1. AV node ablation should not be performed without a pharmacological trial to achieve ventricular rate control (Level of Evidence: C)"

"2. For rate control, intravenous nondihydropyridine calcium channel antagonists, intravenous beta blockers, and dronedarone should not be administered to patients with decompensated HF (Level of Evidence: C)"

Class IIa

"1. A combination of digoxin and a beta blocker (or a nondihydropyridine calcium channel antagonist for patients with HFpEF) is reasonable to control resting and exercise heart rate in patients with AF (Level of Evidence: B)"

"2. It is reasonable to perform AV node ablation with ventricular pacing to control heart rate when pharmacological therapy is insufficient or not tolerated (Level of Evidence: B)"

"3. Intravenous amiodarone can be useful to control heart rate in patients with AF when other measures are unsuccessful or contraindicated. (Level of Evidence: C)"

"4. For patients with AF and rapid ventricular response causing or suspected of causing tachycardia-induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy (Level of Evidence: B)"

"5. For patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is reasonable to use a rhythm-control strategy(Level of Evidence: C)"

Class IIb

"1. Oral amiodarone may be considered when resting and exercise heart rate cannot be adequately controlled using a beta blocker (or a nondihydropyridine calcium channel antagonist in patients with HFpEF) or digoxin, alone or in combination (Level of Evidence: C)"

"2. AV node ablation may be considered when the rate cannot be controlled and tachycardia-mediated cardiomyopathy is suspected (Level of Evidence: C)"

Fournier's gangrene

Physiologic Variables	High Abnormal Values				Normal	Low Abnormal Values
	+4	+3	+2	+1	0	+1	+2	+3	+ 4
Temperature	>41	39-40.0		38.5-39	36-38.4	34-35.9	32-33.9	30-31.9	<29.9
Heart Rate	>180	140-179	110-139		70-109		55-69	40-54	<39
Respiratory Rate	>50	35-49		25-34	12-24	10-11	6-9		<5
Serum Sodium (mmol/L)
Serum Potassium (mmol/L)
Serum Creatinine (mg/100/ml*2 for acute renal failure)
Hematocrit
WBC (Total/mm*1000)
Serum Bicarbonate (Venous,mmol/l)

Region	Gender	Incidence/100,000	Prevalence/100,000
Region 1	M	Incidence	Prevalence
	F	Incidence	Prevalence
Region 2	M	Incidence	Prevalence
	F	Incidence	Prevalence
Region 3	M	Incidence	Prevalence
	F	Incidence	Prevalence
Region 4	M	Incidence	Prevalence
	F	Incidence	Prevalence
Region 5	M	Incidence	Prevalence
	F	Incidence	Prevalence

Zika Prevention

How Long to Wait Before Attempting to Have a Baby in Zika Endemic areas
Presence of Symptoms	Women	Men
Zika symptoms	At least 8 weeks after symptoms start	At least 6 months after symptoms start
No Zika symptoms	Talk with doctor or healthcare provider	Talk with doctor or healthcare provider

Zika sexual transmission

For People Who Have Traveled to an Area with Zika
If you are pregnant	Pregnant women should not travel to areas with Zika. If you must travel to an area with Zika, talk to your healthcare provider.
If your partner is pregnant	Use condoms correctly, every time you have vaginal, anal, or oral sex or do not have sex for the entire pregnancy.
If you and your partner are planning a pregnancy	Discuss your plans for pregnancy with a healthcare provider to determine your risk and the options available.
If you or your partner are not pregnant and are not planning a pregnancy	Men - consider using condoms or not having sex for at least 6 months after travel (if you don’t have symptoms) or for at least 6 months from the start of symptoms (or Zika diagnosis) if you develop Zika. Women- consider using condoms or not having sex for at least 8 weeks after travel (if you don’t have symptoms) or for at least 8 weeks from the start of symptoms (or Zika diagnosis) if you develop Zika.

For People Living in an Area with Zika
If you or your partner are pregnant	Use condoms from start to finish, every time you have vaginal, anal, or oral sex or do not have sex for the entire pregnancy. It is also very important to see a healthcare provider to discuss your options during pregnancy
If you and your partner are planning a pregnancy	Discuss your plans for pregnancy with a healthcare provider to determine your risk and the options available.
If you or your partner are not pregnant and are not planning a pregnancy	Consider using condoms or not having sex as long as there is Zika in the area. If either you or your partner develop symptoms of Zika or have concerns, talk to a healthcare provider and follow the guidelines on the left.

Hand foot and mouth disease

Viruses	Serotypes
Coxsackieviruses	A2, A4 to A10, A16, B2, B3, B5
Echoviruses	1, 4, 7, 19
Enteroviruses	A71

HFMD

Infection	Presentation
Herpes simplex virus stomatitis	• Associated with high grade fever, acute gingivitis and oral ulcerations • The vesicles are small, grouped together and on an erythematous base • Absence of rash on palms and soles • A Tzanck test shows multinucleated giant cells and direct fluorescent antigens test can also help to differentiate hand-foot-and-mouth disease from herpes simplex virus infection
Herpangina	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Bacteremia and sepsis	Leucocytosis >15,000 cells/mL OR serum creatinene level >1.5 times baseline or abdominal tenderness and serum albumin < 3 g/dL
Chickenpox	Hypotension or shock, ileus, megacolon, leucocytosis >20,000 cells/mL OR leucopenia <2,000, lactate >2.2 mmol/L, delirium, fever ≥ 38.5 °C, organ failure
Measles	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Pharyngitis	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Stevens-Johnson syndrome or Erythema multiforme	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Henoch-Schönlein purpura	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Kawasaki disease	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Behcet's disease	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Pemphigus vulgaris	Raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline